← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Certara Uk Limited
Sheffield
$3,173,305
Total funding
6
Grants
Funding over time
peak $500K · FY2014–25$500K$375K$250K$125K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
FDA$3,173,305 · 6
By mechanism
U01$3,173,305 · 6
Investigators at Certara Uk Limited
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Design, Development, Implementation and Validation of a Mechanistic Physiologically-based Pharmacokinetic (PBPK) Framework for the Prediction of the In Vivo Behaviour of Supersaturating Drug Products$284,895
U01 · FY2017 · FD
Formulation toolbox for topically applied drugs to account for physical parameters, dynamic metamorphosis and influence of excipients$249,996
U01 · FY2023 · FD
A State-of-the-Art Virtual Bioequivalence Platform and Case Studies on Complex Formulations, Systemic and Local Concentration-based Bioequivalence$249,980
U01 · FY2023 · FD
Progressing integration of in vitro topical formulation characterisation, release and permeation data to the next level - PBPK based extrapolation to bioequivalence assessment in virtual populations$249,941
U01 · FY2022 · FD
Formulation toolbox for topically applied drugs to account for physical parameters, dynamic metamorphosis and influence of excipients$249,922
U01 · FY2024 · FD
Formulation toolbox for topically applied drugs to account for physical parameters, dynamic metamorphosis and influence of excipients$249,920
U01 · FY2025 · FD
Progressing integration of in vitro topical formulation characterisation, release and permeation data to the next level - PBPK based extrapolation to bioequivalence assessment in virtual populations$249,891
U01 · FY2021 · FD
A State-of-the-Art Virtual Bioequivalence Platform and Case Studies on Complex Formulations, Systemic and Local Concentration-based Bioequivalence$249,837
U01 · FY2024 · FD
Characterization of key system parameters of mechanistic dermal PBPK models in various skin diseases and performance verification of the model using observed local and systemic concentrations$249,443
U01 · FY2018 · FD
Characterization of key system parameters of mechanistic dermal PBPK models in various skin diseases and performance verification of the model using observed local and systemic concentrations$249,406
U01 · FY2019 · FD
Design, Development, Implementation and Validation of a Mechanistic Physiologically-based Pharmacokinetic (PBPK) Framework for the Prediction of the In Vivo Behaviour of Supersaturating Drug Products$248,565
U01 · FY2016 · FD
Development and validation of dermal PBPK modelling platform towards virtual bioequivalence assessment considering population variability$134,950
U01 · FY2016 · FD
Development and validation of dermal PBPK modelling platform towards virtual bioequivalence assessment considering population variability$130,445
U01 · FY2015 · FD
Development and validation of dermal PBPK modelling platform towards virtual bioequivalence assessment considering population variability$126,114
U01 · FY2014 · FD